Immunotech Biopharm Ltd (6978.HK)
HKD 2.47
(8.33%)
HKD 2.47
(8.33%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 405.01 Million CNY | 343.32% |
| 2022 | 91.35 Million CNY | 137.71% |
| 2021 | -242.28 Million CNY | 69.5% |
| 2020 | -794.32 Million CNY | -226.55% |
| 2019 | -243.24 Million CNY | -157.46% |
| 2018 | -94.47 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 206.14 Million CNY | 59.91% |
| 2024 Q1 | 206.14 Million CNY | -49.1% |
| 2023 Q2 | 327.44 Million CNY | 8.34% |
| 2023 FY | 405.01 Million CNY | 343.32% |
| 2023 Q1 | 302.24 Million CNY | 230.84% |
| 2023 Q4 | 405.01 Million CNY | 6.49% |
| 2023 Q3 | 380.33 Million CNY | 16.15% |
| 2022 Q4 | 91.35 Million CNY | 39.9% |
| 2022 Q3 | 65.3 Million CNY | 156.98% |
| 2022 Q2 | -114.6 Million CNY | 15.97% |
| 2022 Q1 | -136.38 Million CNY | 43.71% |
| 2022 FY | 91.35 Million CNY | 137.71% |
| 2021 Q1 | -414.79 Million CNY | 47.78% |
| 2021 Q2 | -405.81 Million CNY | 2.17% |
| 2021 FY | -242.28 Million CNY | 69.5% |
| 2021 Q4 | -242.28 Million CNY | 7.7% |
| 2021 Q3 | -262.49 Million CNY | 35.32% |
| 2020 Q4 | -794.32 Million CNY | 0.9% |
| 2020 FY | -794.32 Million CNY | -226.55% |
| 2020 Q3 | -801.53 Million CNY | -484.18% |
| 2020 Q2 | -137.2 Million CNY | 2.64% |
| 2020 Q1 | -140.92 Million CNY | 42.07% |
| 2019 Q3 | -247.03 Million CNY | 0.0% |
| 2019 Q1 | 174.02 Million CNY | 0.0% |
| 2019 Q4 | -243.24 Million CNY | 1.53% |
| 2019 FY | -243.24 Million CNY | -157.46% |
| 2018 FY | -94.47 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | 630.336% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 92.31% |